DNMT3A alterations associated with myeloid malignancies dictate differential responses to hypomethylating agents

Leuk Res. 2020 Jul:94:106372. doi: 10.1016/j.leukres.2020.106372. Epub 2020 May 13.
No abstract available

Keywords: (DAC); AML; DNA hypomethylating agents (HMA); DNMT3A; Decitabine; MDS.

Publication types

  • Letter
  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • DNA (Cytosine-5-)-Methyltransferases* / genetics
  • DNA (Cytosine-5-)-Methyltransferases* / metabolism
  • DNA Methyltransferase 3A
  • Decitabine / pharmacology*
  • Leukemia, Myeloid, Acute* / enzymology
  • Leukemia, Myeloid, Acute* / genetics
  • Leukemia, Myeloid, Acute* / pathology
  • Mice
  • Mice, Transgenic
  • Myelodysplastic Syndromes* / drug therapy
  • Myelodysplastic Syndromes* / enzymology
  • Myelodysplastic Syndromes* / genetics
  • Myelodysplastic Syndromes* / pathology
  • Neoplasm Proteins* / genetics
  • Neoplasm Proteins* / metabolism

Substances

  • Dnmt3a protein, mouse
  • Neoplasm Proteins
  • Decitabine
  • DNA (Cytosine-5-)-Methyltransferases
  • DNA Methyltransferase 3A